Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2011/05/001758
CTRI/2011/05/001758
Completed
Phase 4

Double Blind, Randomized, Placebo Controlled Trial for Evaluation of Efficacy and Safety of Acne Lotion in the Treatment of Facial Acne Vulgaris

Mayer Organics Pvt Ltd0 sites50 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- Facial Acne Vulgaris

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Facial Acne Vulgaris
Sponsor
Mayer Organics Pvt Ltd
Enrollment
50
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Mayer Organics Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • •Mild to moderate acne irrespective of sex and social status
  • •\-Subjects who have given written informed consent \& ascent (where applicable)

Exclusion Criteria

  • •\-Participation in another study during the past 30 days
  • •\-Cigarette smokers
  • •\-Alcoholics \& drug abusers
  • •\-Pregnant or lactating female
  • •\-Females taking contraceptive pills or hormonal preparation
  • •\-Use of anti\-acne therapy in last 30 days
  • •\-Patients having any systemic illness or using any systemic therapy
  • •\-Patient with hypersensitivity to sulfur containing drugs
  • •\-Poor compliance with study protocol

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
Periappendiceal injection of steroids in ulcerative colitis
CTRI/2012/04/002605PGIMER
Not yet recruiting
Not Applicable
Project goal is eliminate HIV within all systems of the body and to prevent its transmission.HIV/AIDSTuberculosisMalariaupper respiratory tract infections
PACTR201401000720267Health Gateway (PTY) Ltd200
Active, not recruiting
Phase 1
ATherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Patients suffering from unilateral lateral epicondylitis, persistent for more than 3 months or recurrent and not having responded to at least one reference treatmentMedDRA version: 20.0 Level: PT Classification code 10014971 Term: Epicondylitis System Organ Class: 10022117 - Injury, poisoning and procedural complications
EUCTR2017-001709-33-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)150
Active, not recruiting
Not Applicable
Ferric Carboxymaltose Versus Placebo in Patients with Congestive Heart Failure
EUCTR2012-001134-33-DEniversitätsklinikum Ulm
Completed
Not Applicable
Effectivenessof L-Arginine supplementation for treatment of patients with pulmonary tuberculosisTuberculosis.Tuberculosis of lung, confirmed by sputum microscopy with or without culture
IRCT201211179855N2Arak University of Medical Sciences60